Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain.

[10] It is also effective at preventing atrial fibrillation, and has been studied as monotherapy as well as in combination with other medications used to treat irregular heartbeat.

[10] For drugs that are moderate CYP3A inhibitors, such as diltiazem, verapamil, and erythromycin, the dose of ranolazine should be reduced.

[10] Ranolazine also exhibits its effects on the delayed rectifier current (hERG/IKr potassium channels), it readily stimulates myogenesis, it reduces a pro-oxidant inflammation/oxidative condition, and activates the calcium signaling pathway.

[17] Ranolazine prolongs the action potential duration, with corresponding QT interval prolongation on electrocardiography, blocks the INa current, and prevents calcium overload caused by the hyperactive INa current, thus it stabilizes the membrane and reducing excitability.

Afterwards, Phase 2 studies were done; however, it was found that the formulation did not result in adequate plasma concentrations of drug.

[21] In 2008 CV Therapeutics exclusively licensed rights for ranolazine in Europe and some other countries to Menarini.

[26] Ranolazine might constitute a therapeutic option to improve the two main strategies currently used to treat metastatic melanoma.

[27] Research suggests that the transfer of a neurotransmitter from one type of skin cell, melanocytes to another, keratinocytes altered electrical activity and promoted melanoma initiation in preclinical models[28]